Drug Approvals
A Day Never to Forget, Red-Hot Debt Market, Moderna Marches On, Biden Thumbs Up
Plus, Zscaler largely delivers for its owners with its latest results.
There's Good News for 3 Biotech Names
And It comes after one of the best days of the year for the biotech sector.
Would-Be Buyers Should Wait for a Dip in Bullish Prothena
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
Jim Cramer: Why Hasn't the Government Pushed for Mass Vaccination?
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
Jim Cramer: This Rally Is Squarely on Pfizer's Comirnaty
This COVID-19 vaccine is the potential savior of more than just the market.
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
For Now, Moderna Is an Options Play For Me
The shares are only trading at 17 times forward earnings, and might not be fully valued just yet.
Pfizer Price Targets? I've Got Them for You
A subscriber asks. We answer.
Taking Another Look at 2 Stocks I Like While Waiting for Breadth to Broaden
Recent news about Travelzoo and Albireo Pharma offer reasons to think those shares could be heading higher.